Albumin-granulocyte colony stimulating factor fusion protein- Beijing BioFortune/Tianjin SinoBiotech

Drug Profile

Albumin-granulocyte colony stimulating factor fusion protein- Beijing BioFortune/Tianjin SinoBiotech

Alternative Names: Albumin fusion protein – Tianjin; HSA-GCSF; Human Serum Albumin GCSF; rHSA/GCSF fusion protein - Tianjin SinoBiotech

Latest Information Update: 06 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Beijing Bio-Fortune; Tianjin SinoBiotech
  • Class Albumins; Granulocyte colony-stimulating factors; Recombinant fusion proteins
  • Mechanism of Action Granulocyte stimulants; Haematopoiesis stimulants; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Neutropenia

Most Recent Events

  • 06 Sep 2017 Albumin-granulocyte colony stimulating factor fusion protein is still in phase II trials for Neutropenia in China
  • 14 Aug 2017 Tianjin SinoBiotech initiates enrolment in a phase II trial for Neutropenia (Prevention, Chemotherapy-induced) in China (NCT03251768)
  • 10 Apr 2017 Tianjin SinoBiotech completes phase I trial in Neutropaenia (Prevention) in China (SC) (NCT03246009)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top